Rheumatic diseases are one of the main reasons for sick leave and transfer of patients to disabled retirees. Often, due to late diagnosis, irreversible changes occur in the locomotor system, which leads to disability of the patient. Dr. Chishomska It searches for new diagnostic markers for rheumatic diseases, based on multifaceted pioneering research. Positive research results will significantly affect the possibility of early diagnosis and the introduction of a powerful therapeutic intervention, before irreversible structural changes occur in the musculoskeletal system of people with rheumatic diseases.
Dr. Marzyna Chichomska – Graduate of Biotechnology from the University of Warsaw, incl. Breast Cancer Appeal at the Royal Victoria Hospital, Newcastle University School of Medicine. She has completed two postdoctoral fellowships in the Applied Immunology and Transplantation Research Group and in the Musculoskeletal System Research Group at Newcastle University. He is currently doing research at the National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw.
There are nine polyQ diseases in which symptoms are primarily associated with impaired functioning of the nervous system due to the accumulation of mutant proteins in neurons. They are so far incurable. Dibrowska, Massachusetts It investigates the use of genome editing tools in the experimental treatment of polyglutamine (polyQ) diseases. In her research, she used CRISPR-Cas technology to modify the length of the CAG repeat sequence in cells obtained from patients. This approach may be one potential treatment for these diseases in the future.
Magdalena Dąbrowska, MA – Graduated in Medical Analysis at Bialystok Medical University, PhD student at the Institute of Organic Biochemistry of the Polish Academy of Sciences. Awarded with, among others by the Biotechnology Committee of the Polish Academy of Sciences Wacław Szybalski for the best experimental work performed in a Polish laboratory in 2018.
Human blood cells arise from hematopoietic stem cells (HSCs) through the process of hematopoiesis. It is a dynamic but precisely controlled process – CSCs regulate the balance between self-renewal and differentiation into daughter blood cells. However, an imbalance of this balance can cause the uncontrolled growth of the mutant cell population and lead to the development of leukemia. Gońka, MA wants to identify the molecular mechanisms that confer a clonogenic advantage to pre-leukemic HSCs in the hematopoietic niche and explain their role in neoplastic transformation and disease relapse. The goal of her research is to develop better treatment strategies for children with acute leukemia.
Monica Gochka, Massachusetts Graduated from Molecular Biotechnology at Jagiellonian University. In a BA project, she investigated the heterogeneity of bone marrow endothelial cells. The results obtained allowed for the development of another research project for which it received funding under the Diamond Grant Program. During her studies, she did research at the University Children’s Hospital in Krakow and the University of Graz.
Glioblastoma multiforme belongs to the so-called cold tumors in which the response of the immune system is suppressed. Immune cells enter the tumor intensively and their number increases with the degree of malignancy. However, tumor-secreted factors suppress the inflammatory response of immune cells, which begins to support tumor growth rather than nullify it. Therefore, activation of the immune response in these tumors may be necessary for effective immunotherapy. Master Ochocka-Lewicka It studies the formation of immune cells that infiltrate gliomas. Defining the specialized functions of each subtype will help identify the phenotype that is of particular importance in suppressing the immune response.
Master Natalia Oshoka-Luika Biotechnology graduate from Lodz University of Technology. She studied at Vrije Universiteit and Charite Universitätsmedizin. While studying for his Ph.D., he focuses on tumor immunopathology.
Blood cells are derived from hematopoietic stem cells. Normally, stem cells and immature blood cells are found in the bone marrow, but in stressful situations such as infection or bleeding, these cells are released from the bone marrow into the blood as mobilization. One of the proteins involved in this process is granulocyte colony-stimulating factor (G-CSF). In some patients, G-CSF is not effective enough, and new drugs are constantly being searched for. Dr. Szad and colleagues found that cobalt protoporphyrin causes increased production of G-CSF, which transports cells from the bone marrow into the blood. They are now investigating the mechanism of action of cobalt protoporphyrin and whether cells packed in this way could perform their functions better than cells packed with G-CSF.
Dr.. Agata Szadeh Biotechnology graduate from Jagiellonian University. I completed my French and Polish dual master’s studies, then doctoral studies at BBiB College. After I defended my PhD, I left for a post-doctoral fellowship.
Carolina Mikulska Rumenska
The phenomenon of viremia is a kind of cell death. It plays an important role in cancer treatment and may contribute to tissue deterioration in brain injury, kidney disease, and asthma. It’s about the accumulation of large amounts of lipid peroxides, a process that “steals” electrons from fats, which causes cell damage. Produced by lipoxygenases, proteins containing a catalytic center with an iron ion, this family of proteins is the main target of Dr. Mikulska-Rumińska’s tests. Researches the molecular basis of viral disease to identify new drugsIt will allow the introduction of new methods of intervention.
Dr. Karolina Mikulska Rumenska – Graduated from Medical Physics at Nicolas Copernicus University with a PhD in Biophysics. Completed two research scholarships, including a Sciex-NMSch Scholarship at the École Polytechnique Fédérale de Lausanne, and a Postdoctoral Fellowship at the University of Pittsburgh School of Medicine.
“Internet Geek. Food Enthusiast. Thinker. Beer Practitioner. Bacon Specialist. Music Addict. Traveler.”